Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
STAMFORD, Conn., Oct. 16, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at Kidney Week 2017, the American Society of Nephrology's Annual Meeting, to be held October 31 – November 5, 2017 in New Orleans, LA.
Presentations will include clinical data from a recently completed Phase 2b trial of I.V. CR845 in hemodialysis patients suffering from moderate-to-severe pruritus.
Details for the presentations are as follows:
CR845 Oral Presentation:
| Title: | "Randomized, Placebo-Controlled Study on the Efficacy of CR845 in Improving the Quality of Life of Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus” |
| Abstract Number: | SA-OR032 |
| Date / Time: | Saturday, November 4, 2017; 4:42 – 4:54 p.m. CT |
| Presenter: | Frédérique Menzaghi, Ph.D., Senior Vice President, Research and Development, Cara Therapeutics |
CR845 Poster Presentation:
| Poster Title: | "Randomized, Placebo-Controlled Study on the Efficacy of CR845 in Reducing Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients" |
| Poster Number: | FR-PO875 |
| Date / Time: | Friday, November 3, 2017; 9:30 a.m. – 2:30 p.m. CT |
| Presenter: | Robert Spencer, Ph.D., Senior Director, Research and Development, Cara Therapeutics |
Satellite Symposium:
| Title: | "Pioneering a Novel Approach to Relieve CKD-Associated Pruritus: Targeting Peripheral Kappa Opioid Receptors” |
| Date / Time: | Thursday, November 2, 2017; 10:00 – 11:00 a.m. CT |
| Moderator: | Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics |
| Faculty: | James A. Tumlin, M.D., F.A.S.N., Director & Chief Medical Officer, NephroNet, Clinical Trials Consortium; Founder & Medical Director, Southeast Renal Research Institute; Professor, Division of Nephrology, University of Tennessee College of Medicine |
For more information about Kidney Week 2017, visit https://www.asn-online.org/education/kidneyweek/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
